MannKind在2025年第四季度的收入同比增长45.8%，达到1.1196亿美元，主要得益于Furoscix和Afrezza的强劲销售，但公司损失超出预期，导致股价跌至52周来的低点。 MannKind's Q4 2025 revenue rose 45.8% year-over-year to $111.96 million, driven by strong sales of Furoscix and Afrezza, but the company posted a larger-than-expected loss, causing its stock to fall to a 52-week low.

Mannknd报告说,2025年的Q4收入为1.1196亿美元,年同比增长45.8%,高于9 9985万美元的估计数,这是由于Furoscix、Afrezza的强劲销售和特许使用费造成的,但每季度损失每股0.5美元,而预期损失为0.01美元。 MannKind reported Q4 2025 revenue of $111.96 million, a 45.8% year-over-year increase and above the $99.85 million estimate, driven by strong sales of Furoscix, Afrezza, and royalties, but posted a quarterly loss of $0.05 per share, missing the expected loss of $0.01. 尽管收入增长,但股票跌至52周的低点,分析家的评级不一,价格目标降低,而内幕销售和实事求是的技术指标表明近期内疲软。 The stock fell to a 52-week low despite revenue growth, with analysts offering mixed ratings and lowered price targets, while insider selling and bearish technical indicators signaled near-term weakness.